Subject(s)
Anemia/drug therapy , Erythropoietin/therapeutic use , Kidney Failure, Chronic/complications , Polycystic Kidney Diseases/complications , Anemia/blood , Anemia/etiology , Erythropoietin/administration & dosage , Female , Follow-Up Studies , Hematocrit , Humans , Injections, Subcutaneous , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/metabolism , Middle Aged , Polycystic Kidney Diseases/diagnosis , Polycystic Kidney Diseases/metabolism , Recombinant ProteinsSubject(s)
Acute Kidney Injury/chemically induced , Acute Kidney Injury/drug therapy , Antibiotics, Antitubercular/adverse effects , Glucocorticoids/administration & dosage , Prednisolone/administration & dosage , Female , Follow-Up Studies , Glucocorticoids/therapeutic use , Humans , Injections, Intravenous , Middle Aged , Prednisolone/therapeutic use , Tuberculosis, Pulmonary/drug therapySubject(s)
Amyloid Neuropathies/complications , Familial Mediterranean Fever/complications , Hypertension, Renal/complications , Adult , Amyloid Neuropathies/diagnostic imaging , Amyloid Neuropathies/pathology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Biopsy , Blood Pressure , Diuretics/therapeutic use , Follow-Up Studies , Humans , Hypertension, Renal/drug therapy , Hypertension, Renal/physiopathology , Male , UltrasonographySubject(s)
Acute Kidney Injury/therapy , Scleroderma, Systemic/therapy , Acute Kidney Injury/etiology , Combined Modality Therapy , Drug Therapy, Combination , Female , Humans , Hypertension, Malignant/complications , Hypertension, Malignant/therapy , Middle Aged , Renal Dialysis , Scleroderma, Systemic/complications , Time FactorsABSTRACT
An analysis was made in 22 patients with glomerulonephritis taking furosemide as to occurrence of acute renal failure. The authors infer that furosemide administration is not fully safe and the physician should be careful not to initiate hypovolemia and azotemia.
Subject(s)
Acute Kidney Injury/chemically induced , Furosemide/adverse effects , Glomerulonephritis/complications , Acute Kidney Injury/diagnosis , Acute Kidney Injury/prevention & control , Adolescent , Adult , Glomerulonephritis/drug therapy , Humans , Lupus Nephritis/complications , Lupus Nephritis/drug therapy , Middle Aged , Risk FactorsABSTRACT
Iron deficiency involvement in the results of long-term replacement therapy of renal anemia with recormon, a preparation of recombinant human erythropoietin, has been studied in chronic renal failure patients on programmed hemodialysis. The effect of recormon subcutaneous administration to 51 patients was found reduced in 9 patients; in 5 of them the decreased sensitivity to recormon was attributed to iron deficiency. During a year of treatment the percentage of iron-deficient patients rose from 9.1% to 45% as a result of intensive uptake of iron in the course of erythropoiesis. Iron preparation as a corrective treatment contributed to hematocrit increment reducing effective doses of erythropoietin. In addition to routine control of ferritin and iron it is recommended to trace the degree of transferrin saturation in the course of recombinant erythropoietin therapy.